Altimmune announces first quarter 2023 financial results and provides a business update

Initiation of the impact phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (nash) expected mid-2023 top-line 48-week results from the momentum phase 2 obesity trial expected q4 2023 top-line results from the phase 2 trial of heptcell™  in chronic hepatitis b (chb) expected q1 2024 webcast to be held today, may 11, 2023, at 8:30 am edt gaithersburg, md., may 11, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended march 31, 2023, and provided a business update.
ALT Ratings Summary
ALT Quant Ranking